Daily Cosmetic Research Analysis

PURPOSE: To compare safety, functional outcomes, and cosmetic results of periauricular incision (PI) versus modified Blair incision (MBI) in superficial benign parotidectomy. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing parotidectomy with PI versus MBI. PubMed, Embase, Web of Science, Cochrane Library, CBM, CNKI, Wanfang, and VIP databases were searched through April 20, 2025 (PROSPERO: CRD42024620827). Outcomes included transient facial palsy, Frey's syndrome, earlobe numbness, facial deformity, patient satisfaction, salivary fistula, operative time, intraoperative blood loss, postoperative drainage, hospital stay, and incision length. The risk of bias was assessed with RoB 2 and evidence certainty was graded by GRADE. RESULTS: Eleven RCTs encompassing 804 patients (PI 401; MBI 403) met the inclusion criteria. Pooled analysis demonstrated that PI significantly reduced transient facial palsy (RR = 0.60, 95 % CI: 0.39-0.93; moderate certainty), Frey's syndrome (RR = 0.27, 95 % CI: 0.13-0.55; high certainty), earlobe numbness (RR = 0.53, 95 % CI: 0.34-0.84; moderate certainty), and facial deformity (RR = 0.19, 95 % CI: 0.08-0.46; high certainty), as well as higher patient satisfaction (RR = 1.24, 95 % CI: 1.16-1.33; moderate certainty). No significant difference was observed in salivary fistula incidence (RR=0.70; 95 % CI, 0.31-1.59; low certainty) and operative time (SMD=-0.29; 95 % CI, -1.30-0.71; very low certainty). Intraoperative bleeding, postoperative drainage, hospitalization length, and incision length favored PI, but evidence quality was downgraded to low/very low due to high heterogeneity (I² = 72-97 %). CONCLUSION: PI appears to be a safe, cosmetically superior alternative to MBI for small-to-medium benign, superficial parotid tumors. Further multicenter, high-quality RCTs with long-term follow-up are warranted to confirm these findings.

OBJECTIVES: Evidence regarding efficacy and oncological safety of Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) for papillary thyroid carcinoma (PTC) with tumor size 1-2 cm remains limited. This study evaluates the surgical and oncological outcomes of TOETVA in patients with pT1b PTC. METHODS: We conducted a cohort study of 50 consecutive patients with pT1b PTC who underwent TOETVA between January 2019 and December 2024 at Our Hospital. Clinical characteristics, surgical outcomes, and long-term oncological results were evaluated. All procedures were performed by a single experienced endoscopic surgeon. Patients were followed for recurrence and complications. RESULTS: The cohort comprised predominantly female patients (96 %) with mean age 30.5 ± 7.1 years. Mean tumor size was 17 ± 4.6 mm. Lobectomy with isthmusectomy and central neck dissection was performed in 44 patients (88 %) with mean operative time of 85.4 ± 7.5 min, while total thyroidectomy with central neck dissection was performed in 6 patients (12 %) with mean operative time of 122.5 ± 5.2 min. Occult central lymph node metastases were identified in 15 patients (30 %). Mean lymph node yield was 4.2 ± 2.2 nodes. Temporary mental nerve injury occurred in 2 patients (4.0 %) and temporary recurrent laryngeal nerve palsy in 2 patients (4.0 %), all resolving within 3 months. No permanent complications were observed. During mean follow-up of 29.6 months (range 2.4-64.4), no recurrences were detected, and all patients reported satisfactory cosmetic outcomes. CONCLUSIONS: TOETVA represents a safe and effective approach for managing pT1b PTC, demonstrating excellent surgical outcomes and patient satisfaction with minimal complications.

BACKGROUND: Body dissatisfaction can drive individuals to use personal care products, exposing themselves to Benzophenone-3 (BP3). Yet, no study has examined the link between body dissatisfaction and elevated chemical exposures. OBJECTIVES: Our study examines how body dissatisfaction impacts the racial differences in BP3 exposures. METHODS: Using NHANES 2003-2016 data for 3,072 women, we ascertained body dissatisfaction with a questionnaire on weight perception. We ran two generalized linear models with log10-transformed urinary concentrations of BP3 as the outcome variable and the following main predictors: one with race/ethnicity and another combining race/ethnicity and body dissatisfaction. We also conducted stratified analyses by race/ethnicity. We adjusted for poverty income ratio, BMI, urinary creatinine, and sunscreen usage. RESULTS: BP3 levels in Mexican American, Other Hispanic, Other Race, non-Hispanic White, and non-Hispanic Asian women were on average 59 %, 56 %, 33 %, 16 %, and 9 % higher, respectively, compared to non-Hispanic Black women. Racial differences in BP3 levels are further widen with body dissatisfaction. For example, Other Hispanic women perceiving themselves as overweight had 69 % higher BP3 levels than non-Hispanic Black women (p-value = 0.01), while those perceiving themselves as at the right weight had 32 % higher levels (p-value = 0.31). Moreover, minority women perceiving themselves as overweight tended to have higher BP3 levels than those who do not. For example, BP3 levels in Other Hispanic women perceiving themselves as overweight are significantly higher compared to those who do not (73 %, p-value = 0.03). In contrast, such differences in the non-Hispanic White women are minimal (-0.5 %, p-value = 0.98). DISCUSSION: Minority women with body dissatisfaction show elevated BP3 exposure independent of sunscreen usage, implying that their elevated exposures may stem from using other personal care and consumer products. Further research is needed to determine if increased exposure to other toxicants occur among minority women with body dissatisfaction.